Alternatively, Vallejo et al. considered the inhibition of Fos-like antigen 1 (FOSL1), a downstream transcription factor, to show therapeutic promise in KRAS-mutant lung and pancreatic cancer [161, 209]. This evidence concerns the gene KRAS and pancreatic neoplasm.